Article and Video CATEGORIES

Cancer Journey

Search By

Assistant Professor of Medicine, Harvard Medical School

Thoracic Oncologist, Internal Medicine/Medical Oncology, Massachusetts General Hospital

Dana Farber/Harvard Cancer Center

Lung Cancer OncTalk 2024
The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024 and led by Dr. Ibiayi Dagogo-Jack. It included presentations and panel discussions covering general subjects relevant to lung cancer and treatment options and an opportunity to speak with the experts in a Q&A session. Speakers included top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities to become advocates for their own health and well-being.
Author
Ibiayi Dagogo-Jack, MD, Guest Faculty
Image
Lung Cancer OncTalk 2024

The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024, moderated by Dr. Ibiayi Dagogo-Jack, Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at Massachusetts General Hospital, and joined by speakers: Dr. Misty Shields, Indiana University School of Medicine, Dr. Alissa Cooper, Memorial Sloan Kettering Cancer Center, Dr. Angel Qin, University of Michigan Rogel Cancer Center, and Dr. Julia Rotow, Harvard Medical School. 

Topics include:

- Small Cell Lung Cancer

- Antibody Drug Conjugates (ADCs)

- Combo Therapies for EGFR

- Targeted Therapies in Non-Metastatic Lung Cancer

To watch the complete playlist, click here.

To download video transcripts click here.

A huge thank you to our sponsors! #astrazeneca #daiichisankyo #regeneron #takedaoncology

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora